-
1
-
-
77958090924
-
Psoriatic arthritis: A systemic review
-
Cantini F, Niccoli L, Nannini C, Kaloudi O, Bertoni M, Cassarà E. Psoriatic arthritis: A systemic review. Int J Rheum Dis 2010; 13:300-17.
-
(2010)
Int J Rheum Dis
, vol.13
, pp. 300-317
-
-
Cantini, F.1
Niccoli, L.2
Nannini, C.3
Kaloudi, O.4
Bertoni, M.5
Cassarà, E.6
-
2
-
-
84898840784
-
The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection
-
Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, et al. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 2014;33:543-7.
-
(2014)
Clin Rheumatol
, vol.33
, pp. 543-547
-
-
Atteno, M.1
Costa, L.2
Matarese, A.3
Caso, F.4
Del Puente, A.5
Cantarini, L.6
-
3
-
-
84893932253
-
Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: A retrospective observational multicenter study on 15 patients
-
Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: A retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014;33:273-6.
-
(2014)
Clin Rheumatol
, vol.33
, pp. 273-276
-
-
Costa, L.1
Caso, F.2
Atteno, M.3
Giannitti, C.4
Spadaro, A.5
Ramonda, R.6
-
4
-
-
34447519227
-
Immunogenicity of infliximab: How to handle the problem?
-
Belgian IBD Research Group
-
Baert F, De Vos M, Louis E, Vermeire S; Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol Belg 2007;70:163-70.
-
(2007)
Acta Gastroenterol Belg
, vol.70
, pp. 163-170
-
-
Baert, F.1
De Vos, M.2
Louis, E.3
Vermeire, S.4
-
5
-
-
0038476357
-
Immunogenicity of therapeutic monoclonal antibodies
-
Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003;5:172-9.
-
(2003)
Curr Opin Mol Ther
, vol.5
, pp. 172-179
-
-
Pendley, C.1
Schantz, A.2
Wagner, C.3
-
6
-
-
33644625163
-
Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis
-
Aybay C, Ozel S, Aybay C. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int 2006;26:473-80.
-
(2006)
Rheumatol Int
, vol.26
, pp. 473-480
-
-
Aybay, C.1
Ozel, S.2
Aybay, C.3
-
7
-
-
84866630453
-
Immunogenicity to biologics: Mechanisms, prediction and reduction
-
Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp 2012;60:331-44.
-
(2012)
Arch Immunol Ther Exp
, vol.60
, pp. 331-344
-
-
Sethu, S.1
Govindappa, K.2
Alhaidari, M.3
Pirmohamed, M.4
Park, K.5
Sathish, J.6
-
8
-
-
48549102501
-
Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement
-
Aarden L, Ruuls SR, Wolbink GJ. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008;20:431-5.
-
(2008)
Curr Opin Immunol
, vol.20
, pp. 431-435
-
-
Aarden, L.1
Ruuls, S.R.2
Wolbink, G.J.3
-
9
-
-
22944444890
-
Monoclonal antibodies, immunogenicity and associated infusion reactions
-
Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity and associated infusion reactions. Mt Sinai J Med 2005;72:250-6.
-
(2005)
Mt Sinai J Med
, vol.72
, pp. 250-256
-
-
Cheifetz, A.1
Mayer, L.2
-
10
-
-
0037434552
-
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
-
Baret F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
-
(2003)
N Engl J Med
, vol.348
, pp. 601-608
-
-
Baret, F.1
Noman, M.2
Vermeire, S.3
Van Assche, G.4
D'Haens, G.5
Carbonez, A.6
-
11
-
-
70449725246
-
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
-
Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1739-1745
-
-
Radstake, T.R.1
Svenson, M.2
Eijsbouts, A.M.3
Van Den Hoogen, F.H.4
Enevold, C.5
Van Riel, P.L.6
-
12
-
-
33644931095
-
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
-
Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 711-715
-
-
Wolbink, G.J.1
Vis, M.2
Lems, W.3
Voskuyl, A.E.4
De Groot, E.5
Nurmohamed, M.T.6
-
13
-
-
34548192177
-
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation
-
de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252-4.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 1252-1254
-
-
De Vries, M.K.1
Wolbink, G.J.2
Stapel, S.O.3
De Vrieze, H.4
Van Denderen, J.C.5
Dijkmans, B.A.6
-
14
-
-
33747788413
-
High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment
-
Bartelds GM, Wolbink GJ, Stapel S, Aarden L, Lems WF, Dijkmans BA, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006;65:1249-50.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 1249-1250
-
-
Bartelds, G.M.1
Wolbink, G.J.2
Stapel, S.3
Aarden, L.4
Lems, W.F.5
Dijkmans, B.A.6
-
15
-
-
82955189865
-
Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
-
Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 88-91
-
-
Jamnitski, A.1
Krieckaert, C.L.2
Nurmohamed, M.T.3
Hart, M.H.4
Dijkmans, B.A.5
Aarden, L.6
-
16
-
-
84870385642
-
Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
-
Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G, et al. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 2012;64:3850-5.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3850-3855
-
-
Krieckaert, C.L.1
Jamnitski, A.2
Nurmohamed, M.T.3
Kostense, P.J.4
Boers, M.5
Wolbink, G.6
-
17
-
-
65249090248
-
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
-
de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:531-5.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 531-535
-
-
De Vries, M.K.1
Van Der Horst-Bruinsma, I.E.2
Nurmohamed, M.T.3
Aarden, L.A.4
Stapel, S.O.5
Peters, M.J.6
-
18
-
-
84892529958
-
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
-
Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology 2014;53:213-22.
-
(2014)
Rheumatology
, vol.53
, pp. 213-222
-
-
Jani, M.1
Barton, A.2
Warren, R.B.3
Griffiths, C.E.4
Chinoy, H.5
-
20
-
-
84877809247
-
Immunogenicity and autoimmunity during anti-TNF therapy
-
Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013;12:703-8.
-
(2013)
Autoimmun Rev
, vol.12
, pp. 703-708
-
-
Atzeni, F.1
Talotta, R.2
Salaffi, F.3
Cassinotti, A.4
Varisco, V.5
Battellino, M.6
-
21
-
-
79959516247
-
Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis
-
Etanercept Study 301 Investigators
-
Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise M, Dougados M, Wajdula J; Etanercept Study 301 Investigators. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47.
-
(2011)
Clin Exp Rheumatol
, vol.29
, pp. 238-247
-
-
Klareskog, L.1
Gaubitz, M.2
Rodríguez-Valverde, V.3
Malaise, M.4
Dougados, M.5
Wajdula, J.6
-
22
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
Smolen, J.S.4
Davis, D.5
Macfarlane, J.D.6
-
23
-
-
34347267600
-
Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
-
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 921-926
-
-
Bartelds, G.M.1
Wijbrandts, C.A.2
Nurmohamed, M.T.3
Stapel, S.4
Lems, W.F.5
Aarden, L.6
-
24
-
-
33646898772
-
Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis
-
Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-93.
-
(2005)
J Manag Care Pharm
, vol.11
, pp. 383-393
-
-
Ollendorf, D.A.1
Massarotti, E.2
Birbara, C.3
Burgess, S.M.4
-
25
-
-
0036269445
-
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
-
St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 1451-1459
-
-
St Clair, E.W.1
Wagner, C.L.2
Fasanmade, A.A.3
Wang, B.4
Schaible, T.5
Kavanaugh, A.6
-
26
-
-
79960935860
-
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
-
Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445-52.
-
(2011)
Rheumatology
, vol.50
, pp. 1445-1452
-
-
Pascual-Salcedo, D.1
Plasencia, C.2
Ramiro, S.3
Nuño, L.4
Bonilla, G.5
Nagore, D.6
-
27
-
-
70349512283
-
Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review
-
Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review. Inflamm Bowel Dis 2009;15:1264-75.
-
(2009)
Inflamm Bowel Dis
, vol.15
, pp. 1264-1275
-
-
Cassinotti, A.1
Travis, S.2
-
28
-
-
0037379757
-
Preventing antibodies to infliximab in patients with Crohn's disease: Optimize not immunize
-
Sandborn W. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003;124:1140-5.
-
(2003)
Gastroenterology
, vol.124
, pp. 1140-1145
-
-
Sandborn, W.1
-
29
-
-
10744224387
-
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
-
Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:202-13.
-
(2004)
Gastroenterology
, vol.126
, pp. 202-213
-
-
Rutgeerts, P.1
Feagan, B.G.2
Lichtenstein, G.R.3
Mayer, L.F.4
Schreiber, S.5
Colombel, J.F.6
-
30
-
-
33845967407
-
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation
-
de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007;66:133-4.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 133-134
-
-
De Vries, M.K.1
Wolbink, G.J.2
Stapel, S.O.3
De Groot, E.R.4
Dijkmans, B.A.5
Aarden, L.A.6
-
31
-
-
79959573331
-
Antibodies toward infliximab are associated with low infliximab concentrations at treatment initiation and poor infliximab maintenance in rheumatic diseases
-
Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauféron F, Ternant D, et al. Antibodies toward infliximab are associated with low infliximab concentrations at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011;13:R105.
-
(2011)
Arthritis Res Ther
, vol.13
, pp. R105
-
-
Ducourau, E.1
Mulleman, D.2
Paintaud, G.3
Miow Lin, D.C.4
Lauféron, F.5
Ternant, D.6
-
32
-
-
84899719993
-
Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow up
-
Dec 10 (E-pub ahead of print)
-
Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, van der Horst-Bruinsma IE, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow up. Ann Rheum Dis 2013 Dec 10 (E-pub ahead of print).
-
(2013)
Ann Rheum Dis
-
-
Kneepkens, E.L.1
Wei, J.C.2
Nurmohamed, M.T.3
Yeo, K.J.4
Chen, C.Y.5
Van Der Horst-Bruinsma, I.E.6
-
33
-
-
77954893886
-
Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study
-
Adisen E, Aral A, Aybay C, Gürer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. J Dermatol 2010;37:708-13.
-
(2010)
J Dermatol
, vol.37
, pp. 708-713
-
-
Adisen, E.1
Aral, A.2
Aybay, C.3
Gürer, M.A.4
-
34
-
-
33845692734
-
A randomized comparison of continuous vs. Intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
-
Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:1-15.
-
(2007)
J Am Acad Dermatol
, vol.56
, pp. 1-15
-
-
Menter, A.1
Feldman, S.R.2
Weinstein, G.D.3
Papp, K.4
Evans, R.5
Guzzo, C.6
-
35
-
-
84879021925
-
Detection of antibodies to anti-TNF agents in psoriatic patients: A preliminary study
-
Cozzani E, Burlando M, Parodi A. Detection of antibodies to anti-TNF agents in psoriatic patients: A preliminary study. G Ital Dermatol Venereol 2013;148:171-4.
-
(2013)
G Ital Dermatol Venereol
, vol.148
, pp. 171-174
-
-
Cozzani, E.1
Burlando, M.2
Parodi, A.3
-
36
-
-
76749092658
-
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis
-
Lecluse LL, Druesseb RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010;146:127-32.
-
(2010)
Arch Dermatol
, vol.146
, pp. 127-132
-
-
Lecluse, L.L.1
Druesseb, R.J.2
Spuls, P.I.3
De Jong, E.M.4
Stapel, S.O.5
Van Doorn, M.B.6
-
37
-
-
77949431463
-
Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis
-
van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010;69:624-5.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 624-625
-
-
Van Kuijk, A.W.1
De Groot, M.2
Stapel, S.O.3
Dijkmans, B.A.4
Wolbink, G.J.5
Tak, P.P.6
-
38
-
-
34147204834
-
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trail
-
Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trail. Ann Rheum Dis 2007;66:498-505.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 498-505
-
-
Kavanaugh, A.1
Krueger, G.G.2
Beutler, A.3
Guzzo, C.4
Zhou, B.5
Dooley, L.T.6
-
39
-
-
33845660797
-
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with tumor necrosis factor alpha inhibitor infliximab
-
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 3782-3789
-
-
Bendtzen, K.1
Geborek, P.2
Svenson, M.3
Larsson, L.4
Kapetanovic, M.C.5
Saxne, T.6
-
40
-
-
84867399904
-
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis
-
Krieckaert CL, Nurmohamed MT, Wolbing GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis. Ann Rheum Dis 2012;71:1914-5.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 1914-1915
-
-
Krieckaert, C.L.1
Nurmohamed, M.T.2
Wolbing, G.J.3
-
41
-
-
84887489815
-
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis
-
Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 1947-1955
-
-
Garces, S.1
Demengeot, J.2
Benito-Garcia, E.3
-
42
-
-
84882261762
-
Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions
-
Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions. JAMA Intern Med 2013;173:1416-28.
-
(2013)
JAMA Intern Med
, vol.173
, pp. 1416-1428
-
-
Maneiro, J.R.1
Salgado, E.2
Gomez-Reino, J.J.3
-
43
-
-
34548130215
-
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
-
Vermire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31.
-
(2007)
Gut
, vol.56
, pp. 1226-1231
-
-
Vermire, S.1
Noman, M.2
Van Assche, G.3
Baert, F.4
D'Haens, G.5
Rutgeerts, P.6
-
44
-
-
79751477764
-
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
-
Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-8.
-
(2011)
Scand J Gastroenterol
, vol.46
, pp. 310-318
-
-
Steenholdt, C.1
Bendtzen, K.2
Brynskov, J.3
Thomsen O.Ø.4
Ainsworth, M.A.5
-
45
-
-
84867759354
-
Analytical and clinical evaluation of new immunoassay for therapeutic drug monitoring of infliximab and adalimumab
-
Llinares-Tello F, de Salazar JR, Gallego JM, Soler GS, Ramírez CS, Heredia ES, et al. Analytical and clinical evaluation of new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 2012;50:1845-7.
-
(2012)
Clin Chem Lab Med
, vol.50
, pp. 1845-1847
-
-
Llinares-Tello, F.1
De Salazar, J.R.2
Gallego, J.M.3
Soler, G.S.4
Ramírez, C.S.5
Heredia, E.S.6
-
46
-
-
36448985258
-
Monitoring patients treated with anti-TNF alpha biopharmaceuticals: Assessing serum infliximab and anti-infliximab antibodies
-
Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF alpha biopharmaceuticals: Assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007;46:1828-34.
-
(2007)
Rheumatology
, vol.46
, pp. 1828-1834
-
-
Svenson, M.1
Geborek, P.2
Saxne, T.3
Bendtzen, K.4
-
47
-
-
80052505451
-
Differential effect of drug interference in immunogenicity assays
-
Hart MH, De Vrieze H, Wouters D, Wolbink GJ, Aarden LA, Killestein J, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Meth 2011;372:196-203.
-
(2011)
J Immunol Meth
, vol.372
, pp. 196-203
-
-
Hart, M.H.1
De Vrieze, H.2
Wouters, D.3
Wolbink, G.J.4
Aarden, L.A.5
Killestein, J.6
-
48
-
-
85027914593
-
Significant associations of antidrug antibody levels with serum drug through and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis
-
Chen D-Y, Chen Y-M, Tsai W-C, Tseng J-C, Chen Y-H, Hsieh C-W, et al. Significant associations of antidrug antibody levels with serum drug through and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2014;0:1-9.
-
(2014)
Ann Rheum Dis
, pp. 1-9
-
-
Chen, D.-Y.1
Chen, Y.-M.2
Tsai, W.-C.3
Tseng, J.-C.4
Chen, Y.-H.5
Hsieh, C.-W.6
-
49
-
-
84894586484
-
Extent and consequences of antibody formation against adalimumab in patients with psoriasis: One-year follow-up
-
Menting SP, van Lümig PP, de Vries AC, van den Reek JM, van der Kleij D, de Jong EM. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol 2014;150:130-6.
-
(2014)
JAMA Dermatol
, vol.150
, pp. 130-136
-
-
Menting, S.P.1
Van Lümig, P.P.2
De Vries, A.C.3
Van Den Reek, J.M.4
Van Der Kleij, D.5
De Jong, E.M.6
|